Literature DB >> 8857006

Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group.

M A Gerber1, E D Shapiro, G S Burke, V J Parcells, G L Bell.   

Abstract

BACKGROUND: Although the incidence of Lyme disease is highest in children, there are few prospective data on the clinical manifestations and outcomes in children.
METHODS: We conducted a prospective, longitudinal, community-based cohort study of children with newly diagnosed Lyme disease in an area of Connecticut in which the disease is highly endemic. We obtained clinical and demographic information and performed serial antibody tests and follow-up evaluations.
RESULTS: Over a period of 20 months, 201 consecutive patients were enrolled; their median age was 7 years (range, 1 to 21). The initial clinical manifestations of Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 percent, facial-nerve palsy in 3 percent, aseptic meningitis in 2 percent, and carditis in 0.5 percent. At presentation, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia burgdorferi. All but 3 of the 201 patients were treated for two to four weeks with conventional antimicrobial therapy, which was administered orally in 96 percent. All had prompt clinical responses. After four weeks, 94 percent were completely asymptomatic (including the two patients whose parents had refused to allow antimicrobial treatment). At follow-up a mean of 25.4 months later, none of the patients had evidence of either chronic or recurrent Lyme disease. Six patients subsequently had a new episode of erythema migrans.
CONCLUSIONS: About 90 percent of children with Lyme disease present with erythema migrans, which is an early stage of the disease. The prognosis is excellent for those with early Lyme disease who are treated promptly with conventional courses of antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857006     DOI: 10.1056/NEJM199610243351703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  53 in total

Review 1.  Clinical manifestations of tick-borne infections in children.

Authors:  K A Bryant; G S Marshall
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  Neuroborreliosis (Nervous System Lyme Disease).

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 3.  Is neuroborreliosis a medical emergency?

Authors:  John J Halperin
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 4.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

5.  Lyme carditis.

Authors:  Russell Evan Berger; Daniel C McGillicuddy
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

Review 6.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

7.  Peripheral nervous system manifestations of infectious diseases.

Authors:  Kate T Brizzi; Jennifer L Lyons
Journal:  Neurohospitalist       Date:  2014-10

8.  A 10-year-old female with unilateral seventh cranial nerve palsy.

Authors:  Simrran Gohal; Pierre-Philippe Piché-Renaud; Shaun K Morris; Jeremy N Friedman
Journal:  Paediatr Child Health       Date:  2018-05-30       Impact factor: 2.253

9.  Accuracy of Clinician Suspicion of Lyme Disease in the Emergency Department.

Authors:  Lise E Nigrovic; Jonathan E Bennett; Fran Balamuth; Michael N Levas; Rachel L Chenard; Alexandra B Maulden; Aris C Garro
Journal:  Pediatrics       Date:  2017-12       Impact factor: 7.124

Review 10.  Chronic Lyme disease: a review.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.